On July 11, 2019, at the INNOPROM 2019 international exhibition, the Medsintez plant and the Ural State Medical University signed an agreement to join forces to create drugs aimed at reducing mortality caused by cardiovascular and oncological conditions. The new products will appear in 6-7 years. 

'Hopefully, the new stage of our relations will result in a range of innovative drugs. These are, first of all, drugs designed to reduce mortality caused by such major causes as cardiovascular and oncological conditions. And these are new methods of delivering these drugs, because it’s important not only to make a formulation but also to ensure that it is delivered to an organ or system which needs it,' - said Kovtun O., rector of the FGBOU VO UMGU of the Ministry of Health of Russia.

Earlier, the company and the university used to collaborate in clinical trials of Rosinsulin, an insulin substance, and Triazavirin, an antiviral drug. Petrov A., Medsintez's Chairman of the Board of Directors, commented: